Back
Compare AU
Compare JRHG vs. CURE
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the Jpmorgan Global Research En In Eqty (H) Active ETF (JRHG) and the Global X S&P Biotech ETF (CURE). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
JRHG | CURE | |
|---|---|---|
Popularity | N/A | Low |
Pearlers invested | 0 | 66 |
Median incremental investment | $0 | $665.00 |
Median investment frequency | N/A | Monthly |
Median total investment | $0 | $2,039.04 |
Average age group | N/A | > 35 |
Key Summary
JRHG | CURE | |
|---|---|---|
Strategy | JRHG.AX was created on 2023-11-16 by JPMorgan. The fund's investment portfolio concentrates primarily on total market equity. The ETF currently has 41.57m in AUM and 639 holdings. | CURE.AX was created on 2018-11-08 by Global X. The fund's investment portfolio concentrates primarily on health care equity. The ETF currently has 41.75m in AUM and 146 holdings. The Fund aims to provide investors with a return that (before fees and expenses) tracks the performance of the S&P Biotechnology Select Industry Index. |
Top 3 holdings | NVIDIA Corp (5.51 %) Apple Inc (5.14 %) Microsoft Corp (4.53 %) | Revolution Medicines Inc Ordinary Shares (1.70 %) Amicus Therapeutics Inc (1.49 %) Moderna Inc (1.44 %) |
Top 3 industries | Information Technology (55.39 %) Consumer Discretionary (15.31 %) Communication Services (12.99 %) | Health Care (100.00 %) Other (10.24 %) |
Top 3 countries | United States (97.17 %) Switzerland (1.51 %) United Kingdom of Great Britain and Northern Ireland (1.16 %) | |
Management fee | 0.3 % | 0.45 % |
Key Summary
JRHG | CURE | |
|---|---|---|
Issuer | JPMorgan | Global X |
Tracking index | MSCI World ex Australia - AUD - Benchmark TR Net Hedged | S&P Biotechnology Select Industry |
Asset class | ETF | ETF |
Management fee | 0.3 % | 0.45 % |
Price | $74.43 | $63.72 |
Size | $41.840 million | $43.000 million |
10Y return | N/A | N/A |
Annual distribution yield (5Y) | 0.98 % | 5.08 % |
Market | ASX | ASX |
First listed date | 15/11/2023 | 12/11/2018 |
Purchase fee | $6.50 | $6.50 |
Community Stats
JRHG | CURE | |
|---|---|---|
Popularity | N/A | Low |
Pearlers invested | 0 | 66 |
Median incremental investment | $0 | $665.00 |
Median investment frequency | N/A | Monthly |
Median total investment | $0 | $2,039.04 |
Average age group | N/A | > 35 |
Pros and Cons
JRHG | CURE | |
|---|---|---|
Pros |
|
|
Cons |
|
|
JRHG | CURE |
|---|---|
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Lower distribution yield | Higher distribution yield |